Regulatory Affairs
We are specialised on medicinal product authorisation in Switzerland. Of course, for all our services, strategic consultancy as well as taking charge of Swissmedic contacts / negotiations can be offered also.
New authorisations of medicinal products
- New active substances, regular and fast track procedure and procedure with prior notification, temporary authorisation.
- Known active substances, without or with innovation (for example new indication, pharmaceutical form, route of administration and / or dosage recommendation).
- Biosimilars.
- Co-marketing of medicinal products (identical product to an already registered basic preparation).
- Article 13 TPA procedure (medicinal products already authorised abroad).
- Article 14 TPA procedure (e.g., medicinal products authorised in EU/EFTA for at least 10 years).
- For all procedures: adaptation of the EU dossier to Swiss requirements.
Life-Cycle management
- Indication extensions, marketing authorisation extensions (for example new dosage strength, new pharmaceutical form, etc.).
- All types of Variations.
- Update of the prescribing- and patient-information (inclusive translation proof reading, publication on Swissmedicinfo and, if applicable, Compendium).
- Writing and updating succinct statements.
- Changes of packaging materials (inclusive maintenance of your packaging material database).
- Submission of periodic reports (PSUR and PBRER, respectively and Risk Management Plans).
- Modifications of authorisation status (renewal and transfer of marketing authorisations, license cancellations, withdrawal of pack sizes, etc.).
- Direct Health Care Professional Communications.
Orphan Drug Status
- Application for designation of orphan drug status for medicinal products / new active substances.
eCTD
- For all kind of submissions (inclusive baseline submission) we can provide from compilation to validation up to publishing all electronic submission services as required.
Review of promotional material
- Of advertising material intended for professionals as well as for the general public, according to your internal procedures.